DarioHealth (NASDAQ: DRIO), a leader in the global digital-therapeutics (“DTx”) market, today announced its entry into an agreement with one of the largest U.S.
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous systems (“CNS&rd